Cartesian Therapeutics Newsroom

Cartesian Therapeutics Analyst Ratings

BenzingaJul 3 10:24 ET

Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43

BenzingaJul 3 10:24 ET

Buy Rating Affirmed for Cartesian Therapeutics on Descartes-08's Promising Clinical Trial Results

TipRanksJul 3 06:22 ET

Optimistic Buy Rating for Cartesian Therapeutics Ahead of Phase IIb Trial Results

TipRanksJul 1 05:40 ET

Cartesian Therapeutics Analyst Ratings

BenzingaJul 1 05:30 ET

Cartesian Therapeutics Analyst Ratings

BenzingaJun 24 13:32 ET

Cartesian Therapeutics Analyst Ratings

BenzingaJun 14 13:30 ET

Cartesian Therapeutics Analyst Ratings

BenzingaJun 4 08:08 ET

Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target

MT NewswiresJun 4 06:52 ET

Cartesian Therapeutics Analyst Ratings

BenzingaMay 24 07:24 ET

Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning

TipRanksMay 24 01:55 ET

Cartesian Therapeutics Analyst Ratings

BenzingaMay 23 06:51 ET

Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion

TipRanksMay 10 01:35 ET

Cartesian Therapeutics Analyst Ratings

BenzingaMay 9 15:24 ET

Cartesian Therapeutics Analyst Ratings

BenzingaMay 8 11:40 ET

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

BenzingaMay 8 11:40 ET

Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)

TipRanksMay 8 11:35 ET

Cartesian Therapeutics Analyst Ratings

BenzingaApr 23 09:44 ET

Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)

TipRanksApr 23 06:45 ET

Cartesian Therapeutics Analyst Ratings

BenzingaApr 9 12:18 ET